STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer

被引：0
|
作者：
Abdi Ghaffari
Nichole Peterson
Kasra Khalaj
Natasha Vitkin
Andrew Robinson
Julie-Ann Francis
Madhuri Koti
机构：
[1] Queen’s University,Department of Biomedical and Molecular Sciences
[2] Queen’s University,Department of Obstetrics and Gynecology, Kingston Health Sciences Center
[3] Queen’s University,Department of Oncology, Kingston Health Sciences Center
[4] Queen’s University,Cancer Biology and Genetics, Queen’s Cancer Research Institute
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：440 / 449
页数：9
相关论文
共 50 条
  • [41] Molecular Biomarkers of Response to PD-1/PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
    Tu, Megan M.
    Ng, Terry L.
    De Jong, Horns C.
    Zuiverloon, Tahlita C. M.
    Fazzari, Francesco G. T.
    Theodorescu, Dan
    BLADDER CANCER, 2019, 5 (02) : 131 - 145
  • [42] Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer
    Dahl, Erika S.
    Buj, Raquel
    Leon, Kelly E.
    Newell, Jordan M.
    Imamura, Yuka
    Bitler, Benjamin G.
    Snyder, Nathaniel W.
    Aird, Katherine M.
    MOLECULAR CANCER RESEARCH, 2019, 17 (08) : 1710 - 1720
  • [43] BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines
    Shen, Yen Ting
    Evans, James C.
    Zafarana, Gaetano
    Allen, Christine
    Piquette-Miller, Micheline
    MOLECULAR PHARMACEUTICS, 2018, 15 (07) : 2742 - 2753
  • [44] Ovarian Cancer Response Scoring (OCRS): Validation of a system to quantify histopathological response to neoadjuvant chemotherapy in high-grade serous ovarian cancer
    Singh, N.
    Said, I.
    Faruqi, A.
    Gilks, B.
    Le, N.
    Boehm, S.
    VIRCHOWS ARCHIV, 2014, 465 : S40 - S40
  • [45] Targeting macrophages and regulatory T cells improves response to chemotherapy in high-grade serous ovarian cancer
    Elorbany, Samar
    Berlato, Chiara
    Carnevalli, Larissa
    Barry, Simon
    Maniati, Eleni
    Wang, Jun
    Manchanda, Ranjit
    Kzhyshkowska, Julia
    Balkwill, Frances
    CANCER RESEARCH, 2024, 84 (06)
  • [46] Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
    Liu, Ping
    Chen, Ruoxu
    Zhang, Xudong
    Fu, Ruiting
    Tao, Lin
    Jia, Wei
    BMC GENOMICS, 2022, 23 (01)
  • [47] Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
    Ping Liu
    Ruoxu Chen
    Xudong Zhang
    Ruiting Fu
    Lin Tao
    Wei Jia
    BMC Genomics, 23
  • [48] Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
    Wong-Brown, Michelle W.
    van der Westhuizen, Andre
    Bowden, Nikola A.
    BMC CANCER, 2022, 22 (01)
  • [49] Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
    Michelle W. Wong-Brown
    Andre van der Westhuizen
    Nikola A. Bowden
    BMC Cancer, 22
  • [50] High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer
    Olmez, Fatma
    Oglak, Suleyman Cemil
    Olmez, Omer Fatih
    Akbayir, Ozgur
    Yilmaz, Ercan
    Akgol, Sedat
    Konal, Merve
    Seyhan, Niyazi Alper
    Kinter, Alp Koray
    TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2022, 19 (03) : 246 - 256
12345